Journal of Genetics and Gene Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Update in Genetic Colerectal Cancer Syndrome

Colorectal cancer is the third common cancer in the world. About 3-5% of the patients are carrier of genetic syndrome with high risk of colorectal cancer (CRC) and others malignancy. 20-30% of the patients with new diagnosed colorectal cancer had a family history of colorectal cancer. The most common hereditary syndrome is Lynch Syndrome (HNPCC hereditary non-polyposis colorectal cancer). Other syndromes with increased number of polyps include Familial adenomatous polyposis (FAP), attenuated FAP and MUTYH associated Polyposis (MAP). Genetics: lynch syndrome is characterized by a germline mutation at a defective DNA mismatch repair (MMR) genes, with a high level of microsatellite instability. The most common genes involved in the syndrome are MLH1, MSH2, MSH6, PMS2 and EpCAM. FAP caused by APC gene defects and MAP caused by a defect in the MUTYH gene. Lynch syndrome and FAP are inherited autosomal dominant, while MAP inherited autosomal recessive. Diagnosis is made by genetic investigation, founder mutation and gene sequencing. Cancer risk: Mutation carrier of the different types of the syndromes has increased risk of colonic and extra-colonic neoplasm. The lifetime CRC risk is estimated to be 50-80% in HNPCC and about 100% in FAP. The risk of the malignancy development is depending on mutation and gene. Clinical setting: Amsterdam criteria and revised Bethesda criteria were developed to identify persons and families with high risk form Lynch syndrome. Patients with FAP are characterized by thousands of polyps and MAP patients by 10-100 of polyps. Universal screening for lynch syndrome: should patients with colorectal cancer or endometrial cancer undergo screening by immunohistochemistry (IHC) or microsatellite instability (MSI) for lynch syndrome? Yes, several recommendations include the universal screening for all diagnosed patients under age 70 years. The Surveillance recommendation and treatment with aspirin or cox2 will be discussed. All the above points will be updated and discussed during the lecture.

Special Features

Full Text

View

Track Your Manuscript

Media Partners

GET THE APP